150 related articles for article (PubMed ID: 32374931)
1. Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores.
Ferries L; Gillibert A; Duvert-Lehembre S; Corbaux C; Alexandre M; Prost-Squarcioni C; Caux F; Delaporte E; Litrowski N; Boulard C; Murrell DF; Joly P; Hébert V
Br J Dermatol; 2020 Nov; 183(5):944-945. PubMed ID: 32374931
[No Abstract] [Full Text] [Related]
2. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
Kalinska-Bienias A; Jakubowska B; Kowalewski C; Murrell DF; Wozniak K
Adv Med Sci; 2017 Mar; 62(1):92-96. PubMed ID: 28208086
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires.
Saleh MA; Zaraa I; Doss N; Saleh NA; Murrell DF
An Bras Dermatol; 2019; 94(4):399-404. PubMed ID: 31644610
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes.
Patsatsi A; Kokolios M; Kyriakou A; Lamprou F; Stylianidou D; Tsapas A; Goulis DG; Murrell DF; Sotiriadis D
Acta Derm Venereol; 2017 Oct; 97(9):1145-1147. PubMed ID: 28660281
[TBL] [Abstract][Full Text] [Related]
5. The effect of autoimmune blistering diseases on work productivity.
Wang EQ; Radjenovic M; Castrillón MA; Feng GHY; Murrell DF
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1959-1966. PubMed ID: 29730897
[TBL] [Abstract][Full Text] [Related]
6. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire.
Sebaratnam DF; Hanna AM; Chee SN; Frew JW; Venugopal SS; Daniel BS; Martin LK; Rhodes LM; Tan JC; Wang CQ; Welsh B; Nijsten T; Murrell DF
JAMA Dermatol; 2013 Oct; 149(10):1186-91. PubMed ID: 23925444
[TBL] [Abstract][Full Text] [Related]
7. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.
Tjokrowidjaja A; Daniel BS; Frew JW; Sebaratnam DF; Hanna AM; Chee S; Dermawan A; Wang CQ; Lim C; Venugopal SS; Rhodes LM; Welsh B; Nijsten T; Murrell DF
Br J Dermatol; 2013 Nov; 169(5):1000-6. PubMed ID: 24102329
[TBL] [Abstract][Full Text] [Related]
8. Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA.
Sebaratnam DF; Okawa J; Payne A; Murrell DF; Werth VP
Qual Life Res; 2015 Sep; 24(9):2257-60. PubMed ID: 25795375
[TBL] [Abstract][Full Text] [Related]
9. Outcome measures for autoimmune blistering diseases.
Zhao CY; Murrell DF
J Dermatol; 2015 Jan; 42(1):31-6. PubMed ID: 25558950
[TBL] [Abstract][Full Text] [Related]
10. The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
Wijayanti A; Zhao CY; Boettiger D; Chiang YZ; Ishii N; Hashimoto T; Murrell DF
Acta Derm Venereol; 2017 Jan; 97(1):24-31. PubMed ID: 27244117
[TBL] [Abstract][Full Text] [Related]
11. Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.
Krain RL; Kushner CJ; Tarazi M; Gaffney RG; Yeguez AC; Zamalin DE; Pearson DR; Feng R; Payne AS; Werth VP
Front Immunol; 2019; 10():2571. PubMed ID: 31781098
[TBL] [Abstract][Full Text] [Related]
12. Quality of life index in autoimmune bullous dermatosis patients.
Penha MÁ; Farat JG; Miot HA; Barraviera SR
An Bras Dermatol; 2015; 90(2):190-4. PubMed ID: 25830988
[TBL] [Abstract][Full Text] [Related]
13. Beyond the skin: disease parameters in pemphigus.
Viti G; Forcella C; Feliciani C; Murrell DF
Ital J Dermatol Venerol; 2021 Apr; 156(2):147-150. PubMed ID: 33960750
[TBL] [Abstract][Full Text] [Related]
14. Objective scoring systems for disease activity in autoimmune bullous disease.
Sebaratnam DF; Murrell DF
Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
[TBL] [Abstract][Full Text] [Related]
15. Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses.
Heelan K; Hitzig SL; Knowles S; Drucker AM; Mittmann N; Walsh S; Shear NH
J Cutan Med Surg; 2015; 19(6):546-54. PubMed ID: 25888597
[TBL] [Abstract][Full Text] [Related]
16. Development of an Excel® spreadsheet to document disease activity in autoimmune bullous disease.
Sebaratnam DF; Venugopa SS; Murrell DF
Acta Dermatovenerol Croat; 2013; 21(3):207-8. PubMed ID: 24183229
[No Abstract] [Full Text] [Related]
17. Achieving Diagnosis: Importance of Proper Biopsy in Autoimmune Bullous Disorders.
Patel VM; Sylvester M; Baldev K; John AM; Lambert WC
Skinmed; 2017; 15(2):129-131. PubMed ID: 28528608
[No Abstract] [Full Text] [Related]
18. Management of autoimmune bullous diseases in France: a nationwide network of 30 centers.
Meyer N; Paul C; Joly P
Dermatol Clin; 2011 Oct; 29(4):659-62. PubMed ID: 21925014
[TBL] [Abstract][Full Text] [Related]
19. [Immunohistology of bullous autoimmune skin diseases].
Ledoux M; Achten G; Shahabpour M
Acta Stomatol Belg; 1991 Apr; 88(1):31-8. PubMed ID: 1950839
[TBL] [Abstract][Full Text] [Related]
20. [Information sources and therapeutic education in autoimmune bullous diseases].
Le Roux-Villet C; Facy H; Gentile I; Natier L
Soins; 2023 Nov; 68(880):16-17. PubMed ID: 37931990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
